Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neonatal group B streptococcal infections

K M Boyer1

  • 1Rush Medical College, Chicago, Illinois, USA.

Current Opinion in Pediatrics
|February 1, 1995
PubMed
Summary

Group B Streptococcus (GBS) causes severe neonatal infections globally. Research explores effective prevention through ampicillin chemoprophylaxis and promising conjugate vaccines currently in human trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic testing for congenital toxoplasmosis.

The Pediatric infectious disease journal·2001
Same author

Disability benefits: what is the Social Security Administration thinking?

The Journal of medical practice management : MPM·2000
Same author

RSV and the timing of surgery for congenital heart disease.

Critical care medicine·1999
Same author

Exploring effects of different pictorial stimuli on written expression.

Psychological reports·1999
Same author

Alternative algorithms for prevention of perinatal group B streptococcal infections.

The Pediatric infectious disease journal·1998
Same author

Treatment of acyclovir-resistant herpes simplex virus keratitis in a patient with Wiskott-Aldrich syndrome.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1997

Area of Science:

  • Neonatal infections
  • Bacterial pathogenesis
  • Vaccine development

Background:

  • Group B Streptococcus (GBS) is a primary cause of life-threatening neonatal infections worldwide.
  • Current incidence in the US is 1.8 cases per 1000 live births, with a 10-20% fatality rate.
  • Understanding GBS pathogenesis informs new treatment strategies for septic shock and meningitis.

Purpose of the Study:

  • To review current and emerging strategies for preventing and treating Group B Streptococcus neonatal infections.
  • To highlight the efficacy of intrapartum chemoprophylaxis and conjugate vaccines.

Main Methods:

  • Review of existing literature on GBS pathogenesis, treatment, and prevention.
  • Analysis of data on ampicillin chemoprophylaxis effectiveness and cost-effectiveness.
  • Summary of findings from preclinical (mouse models) and early-stage human trials of GBS conjugate vaccines.

Main Results:

  • Selective intrapartum chemoprophylaxis with ampicillin is effective and cost-effective, gaining acceptance.
  • GBS conjugate vaccines demonstrated efficacy in preventing neonatal infection in a mouse model.
  • Human trials for GBS conjugate vaccine safety and immunogenicity are underway.

Conclusions:

  • Advances in understanding GBS pathogenesis are driving new therapeutic approaches.
  • Ampicillin chemoprophylaxis represents a proven preventive measure.
  • GBS conjugate vaccines hold significant promise for preventing neonatal infections and are progressing to human trials.

Related Experiment Videos